USPTO Rejects ATAI Life Sciences’ Ibogaine Co-Administration Patent Application: Implications and Insights
![](https://psytelligence.com/wp-content/uploads/2023/07/Screen-Shot-2023-07-20-at-9.21.57-AM-1024x569.png)
The application for patent 17/941,648 bu ATAI Life Sciences is being disapproved at non-final stage by the United States Patent and Trademark Office (USPTO). Their proposed combination treatment involving co-administration of Ibogaine with a metabolism inhibitor was intended to create safer psychotropic therapies. Porta Sophia, a non-profit organization dedicated to creating an ethical and equitable […]